On April 6, 2026 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, reported the publication of two abstracts that will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company will present previously undisclosed data demonstrating the expanding potential of its Ac-225 radiotherapy platform across both solid tumors and hematologic malignancies. Both presentations will occur on April 21, 2026 in the session Radiopharmaceutical Platforms for Theranostic Precision Oncology.
Sandesh Seth, Actinium’s Chairman and CEO, said, "These new data further validate the strength and versatility of our Ac-225 radiotherapy platform. ATNM-400 continues to show compelling pan-tumor activity, including activity in tumors resistant to current targeted therapies, supporting its potential as a first-in-class asset in large solid tumor indications. In parallel, Actimab-A’s newly identified mechanism of transcriptional reprogramming provides important insight into its mutation-agnostic activity and ability to enhance standard-of-care therapies. Together, these findings reinforce our strategy to build a differentiated pipeline with multiple value-driving opportunities."
ATNM-400 AACR (Free AACR Whitepaper) 2026 Presentation Details
Poster Number: 5824
Session: Radiopharmaceutical Platforms for Theranostic Precision Oncology
Date & Time: April 21, 2026 – 2:00 PM – 5:00 PM PT | Poster Section 16, Board #18
Actimab-A AACR (Free AACR Whitepaper) 2026 Presentation Details
Poster Number: 5827
Session: Radiopharmaceutical Platforms for Theranostic Precision Oncology
Date & Time: April 21, 2026 – 2:00 PM – 5:00 PM PT | Poster Section 16, Board #21
(Press release, Actinium Pharmaceuticals, APR 6, 2026, View Source [SID1234664178])